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Introduction 
Vitamin D is a steroid hormone that 
regulates transcription of over 900 genes and 
is involved in nearly every organ system in 
the human body.1 Vitamin D insufficiency 
and deficiency are increasing in prevalence 
worldwide, yet are commonly unrecognized 
clinically, even though serum vitamin D 
levels can be measured, and vitamin D 
repletion is inexpensive and well tolerated. 
Classic manifestations of vitamin D 
deficiency include symmetric low back pain, 
proximal muscle weakness, myalgias, and 
bone pain.1  Most cases of deficiency or 
insufficiency in the modern era, however, 
are not accompanied by such dramatic 
symptoms. Nonetheless, vitamin D 
screening has become a routine part of the 
primary medical care of patients in many 
medical practices.  In spite of the broad 
practice of screening for vitamin D 
deficiency or insufficiency, we are left with 
conflicting data on what constitutes a normal 
vitamin D level, and even more controversy 
surrounding whether vitamin D should be 
screened routinely. 
 
What is a normal vitamin D level? 
Vitamin D status is assessed by measuring 
the prohormone 25-hydroxyvitamin D, which 
is an indicator of supply rather than function, 
as it must be hydroxylated in the kidney to 
form the active metabolite 1,25-dihydroxy-
vitamin D.  25-hydroxyvitamin D is the most 
stable and plentiful metabolite of vitamin D in 
human serum, though, with a half-life of 
about three weeks, making it a very attractive 
metabolite for screening purposes. 
 
 
 
Precisely defining vitamin D deficiency or 
insufficiency on the basis of 25-hydroxy-
vitamin D values is a matter of much debate, 
as a normal range cannot be defined based on 
population norms, as might be the case with 
other hormone levels.  A functional definition 
of optimal vitamin D status is the 25-
hydroxyvitamin D level that maximally 
suppresses parathyroid hormone (PTH) 
secretion, as the major stimulus for PTH 
secretion is a low level of serum ionized 
calcium.2  An alternative, albeit less elegant, 
definition might be the level at which there 
appears to be protection against adverse 
skeletal outcomes such as fracture and falls,3 
indices of bone remodeling, decreased bone 
mineral density in cross-sectional studies, or 
fractures in observational studies.4,5 
In the cross-sectional National Health 
and Nutrition Examination Survey 
(NHANES III) survey, serum 25-
hydroxyvitamin D concentration was 
associated with bone mineral density in 
community-dwelling women and men aged 
at least 20 years and up.6  A cause-and-
effect relationship, however, was difficult to 
prove, given that low vitamin D intake and 
low bone density might simply reflect that 
healthier persons who exercise more (thus 
have greater bone density) may spend more 
time outside in the sun (thus have higher 25-
hydroxyvitamin D levels).7,8  
The Women’s Health Initiative calcium 
and vitamin D supplementation trial 
revealed that hipbone mineral density was 
1.06 percent higher in women receiving 
calcium   and   vitamin   D   than   in women  
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receiving placebo after nine years, but the 
lumbar spine total bone mineral density in 
supplemented subjects did not differ 
significantly from those receiving placebo 
during this interval.8,9  In the nested case-
control study, the 25-hydroxyvitamin D 
baseline level was 46.0 +/- 22.6 nmol/L 
among participants who had hip fracture and 
48.4 +/- 23.5 nmol/L among controls (p = 
0.17). No statistically significant interactions 
were found between calcium with vitamin D 
supplementation and baseline 25-
hydroxyvitamin D level with respect to 
either hip or total fractures.8 
A cross-sectional, observational study 
conducted at 61 sites across North America 
showed that 52 percent of postmenopausal 
women receiving therapy for osteoporosis 
had 25-hydroxyvitamin D levels of less than 
30 ng/ml.4  As it stands, most experts define 
vitamin D deficiency as a serum 25-
hydroxyvitamin D level of less than 20 
ng/mL (50 nmol/L) and insufficiency as a 
serum 25-hydroxyvitamin D level of 20 to 
30 ng/mL (50 to 75 nmol/L).5,10  
Two rationales exist for setting the low 
end of the normal range for 25-
hydroxyvitamin D at 30 ng/ml.11  First, the 
serum level of parathyroid hormone (PTH) 
rises when the vitamin D level falls below 
30 ng/ml. Second, active calcium absorption 
is optimal when the vitamin D level is 30 
ng/ml.12,13  However, an Institute of 
Medicine14 report questions both of these 
tenets.15 
More recently, vitamin D insufficiency 
has been used to describe low levels of 
serum 25-hydroxyvitamin D that may be 
associated with other (non-skeletal) disease 
outcomes.9 Interpreting the import of a 
serum level of 25-hydroxyvitamin D in the 
insufficient range (i.e., 10-30 ng/ml) is 
challenging for at least three reasons.  First, 
most reference laboratories have raised the 
lower boundary of normal range to 30 
ng/ml.   
Second, the precision and accuracy of 
various vitamin D assays, especially in non-
reference laboratories, remains problematic. 
High performance liquid chromatography is 
considered the gold standard method, but 
liquid chromatography-tandem mass 
spectrometry is currently among the most 
accurate measures of the separate 
contributions of both 25-hydroxyvitamin D2 
and D3 to total 25-hydroxyvitamin D 
concentrations.4 Different 25-hydroxy-
vitamin D assays, though, yield markedly 
differing results; so different that whether an 
individual is found to have low or normal 
vitamin D status sometimes may be a 
function of the laboratory used. The 
chemiluminescent assay tends to give higher 
values of 25-hydroxyvitamin D.  In a study 
in which a single serum sample showing 
adequate vitamin D status was sent to 
multiple laboratories, the level was correctly 
identified as adequate in one laboratory, but 
was considered insufficient in others, with 
differences of up to 17 ng/ml.16   This 
discrepancy between labs and between 
assays has led to calls for measurement of 
25-hydroxyvitamin D to be standardized.  
Third, seasonal variation exists in both 
exposure to sunlight and in dietary intake of 
vitamin D, with levels typically highest 
during summer and lowest during winter.5,17  
A study of Asian adults in the United 
Kingdom showed that 82 percent had 25-
hydroxyvitamin D levels less than 12 ng/ml 
during the summer season, with the 
proportion increasing to 94 percent during 
the winter months.18  Vitamin D stored in 
body fat is released during winter, when 
vitamin D cannot be produced. 
Previously, according to the World 
Health Organization (WHO), a 25-
hydroxyvitamin D level below 10 ng/ml was 
classified as deficient and a level below 20 
ng/ml was classified as insufficient.13  
However, with relatively recent changes in 
laboratory reference ranges, a normal level 
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now is defined by WHO as 30-76 ng/ml (75-
190 nmol/L).4,13,19 
The 2011 Dietary Reference Intake 
(DRI) for vitamin D based on bone health 
outcomes suggested that levels of 16 ng/ml 
meet  the needs of approximately half the 
population and levels of at least 20 ng/ml 
meet the needs of 97.5% of the population 
(similar to the Required Dietary Allowance; 
RDA).14 In 2010, the International 
Osteoporosis Foundation issued a statement 
on vitamin D status, based on observational 
data, recommending a target serum vitamin 
D level of 30 ng/ml in all elderly persons 
and vitamin D intakes as much as 2000 
IU/day.13 
 
Should we screen patients for vitamin D 
deficiency? 
Given the conflicting but generally 
positive data outlined above, two arguments 
can be made in regards to vitamin D 
screening and/or treatment.   
 
Patients routinely should be screened for 
vitamin D deficiency. 
Patients should be screened for vitamin 
D deficiency for two reasons. First, 
screening detects potential vitamin D-
associated disease states.  Second, screening 
better determines the amount and duration of 
vitamin D supplementation needed to treat 
the disease state in question. 
The serum 25-hydroxyvitamin D level is 
the best indicator for judging vitamin D 
status in patients with potential vitamin D-
related disease states.20  For example, severe 
deficiency (< 10 ng/mL) could be associated 
with osteomalacia or rickets, and moderate 
deficiency (10-25 ng/mL) may be associated 
with an increased risk of osteoporosis or 
secondary hyperpara-thyroidism. 
Establishing the patient’s untreated 
vitamin D level will give insight into the 
type of bone disease present, if any, and 
reduce the likelihood of causing harm 
through over-supplementation.  Vitamin D 
toxicity causes hypercalcemia typically at 
serum levels over 120 ng/ml, and most often 
when it is consistently greater than 150-
200ng/ml, although toxicity has been 
reported in patients with normal renal 
function and without primary hyper-
parathyroidism at levels as low as 80 
ng/mL.9,13,21,22 The effects of toxicity 
(hypercalciuria, nephrocalcinosis, and 
calcium containing kidney stones) may take 
up to 6-9 months to abate after stopping 
vitamin D supplementation. 
It commonly is assumed that the serum 
25-hydroxyvitamin D level will increase by 
1 nmol/L for every 57-100 IU of daily 
vitamin D intake taken as a loading dose, 
but this does not necessarily account for 
body weight and vitamin D metabolism.13,23 
Knowing the 25-hydroxyvitamin D level at 
baseline allows for a calculation of the 
amount of vitamin D supplementation 
needed to achieve a target vitamin D level, 
accounting for body weight: 
 
∆ 25-hydroxyvitamin D = 0.025 x (dose 
IU/kg body weight) 
 
therefore, 
 
Loading Dose = 100 x (Desired Actual 
ng/mL of 25-hydroxyvitamin D) x Weight 
(kg)  
 
This formula is not valid for cases of 
malabsorption, and its accuracy is unknown 
for patients over 125 kg.  It also does not 
calculate the required maintenance dose.23  
In addition to supplying information 
needed to calculate the required dose of 
vitamin D, knowledge of a baseline vitamin 
D level theoretically can help with timing of 
therapies.  For example, administration of 
anti-resorptive therapy (e.g., bisphos-
phonates, estrogen, raloxifene, or 
denosumab) to a vitamin D deficient patient 
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with osteomalacia may cause severe 
hypocalcemia.24  Such a patient would need 
to normalize her vitamin D level before 
starting antiresorptive therapy. 
 
Patients with suspected vitamin D deficiency 
should be treated empirically. 
The serum 25-hydroxyitamin D level is 
an expensive test, and the cost is 
compounded when one considers that many 
patients deemed insufficient will undergo 
testing two or more times.  No evidence-
based consensus guidelines exist regarding 
screening for vitamin D deficiency/ 
insufficiency or for using serum markers for 
medical management of individual 
patients.15   A more reasonable interpretation 
of current literature suggests that physicians 
should judge, based on an individual 
patient’s risk of insufficiency or deficiency 
of vitamin D, whether measuring the 25-
hydroxyvitamin D level will assist in 
diagnosing disease and/or significantly 
change medical management. 
The National Health and Nutrition 
Examination Survey III data revealed that 
more than 90 percent of the pigmented 
population of the United States (Blacks, 
Hispanics, and Asians) now suffer from 
vitamin D insufficiency (defined as a 25-
hydroxyvitamin D level less than 30 ng/ml), 
with nearly three-fourths of the white 
population in the United States also being 
vitamin D insufficient.19,25  In general, 
males, children, leaner persons, and non-
Hispanic whites have higher 25-
hydroxyvitamin D concentrations than do 
females, adults, obese persons, non-Hispanic 
blacks, and Mexican-Americans.26  
Conditions that cause very low levels 
(i.e., < 10 ng/ml) of 25-hydroxyvitamin D 
include use of anticonvulsant medications 
(e.g., phenobarbital, phenytoin) and long-
term use of glucocorticoids, rifampin, 
cholestyramine,5,27,28 poor dietary intake 
plus negligible sun exposure, or mal-
absorption due to inflammatory bowel 
disease, gluten sensitive enteropathy, gastric 
surgery, biliary disease, or intestinal 
overgrowth.10,13  These observations indicate 
that a person’s risk for vitamin D deficiency 
could be established in many cases without 
an expensive laboratory study, and that the 
resulting financial resources could 
alternatively be put toward vitamin D 
replacement. 
The   very   values   defining   vitamin D 
insufficiency are a moving target. 25-
hydroxyvitamin D levels tend to be seasonal 
in the Midwest.  Should a value of 30 ng/ml 
be sought all twelve months of the year, or 
should a winter level of 20 ng/ml be 
considered the “seasonal equivalent” of a 
summer value of 30 ng/ml?  The long-term 
data do not exist to make such a distinction.  
When laboratories across the US began 
using 30 ng/ml as their cut-off between 
sufficient and insufficient vitamin D blood 
levels, many physicians began instituting 
vitamin D supplementation in their patients.  
Since the Institute of Medicine’s (IOM) 
decision to recognize a level of 20 ng/ml as 
meeting the requirements of 97.5% of the 
population, many of those same patients 
would now be considered replete without 
supplementation.14  
Empiric supplementation of vitamin D 
appears safe, and the IOM raised its daily 
recommendations, stating most Americans 
and Canadians up to age 70 need no more 
than 600 IU/d and that older patients may 
need as much as 800 IU/d, along with diet 
and sunlight, to maintain health.14 To 
illustrate the apparently wide therapeutic 
window of vitamin D though, the same 
report increased the upper limit of safe 
supplementation to 4,000 IU (100 mcg/day) 
for adults.  Typical sun exposure of a person 
in a bathing suit of one minimal erythematic 
dose (which causes a slight pinkness to the 
skin) is equivalent to ingesting 20,000 IU of 
vitamin D.29 
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Summary 
Low vitamin D status is increasing in 
prevalence worldwide. The role of screening 
for vitamin D deficiency in routine medical 
care though is still uncertain.  Unresolved 
issues of vitamin D testing include definition 
of a normal serum level; prediction of a new 
serum vitamin D level as a function of 
dosage of vitamin D, given complex patient 
factors including age, endogenous 
production, season and geographic locale, 
ethnic background, diet, and underlying 
health conditions; and the fact that 
epidemiological studies appear to show 
different effective vitamin D levels for 
different disease states. 
Large-scale randomized clinical trials 
and consensus cut-points for vitamin D level  
 
are needed to avoid both under- and over-
treatment.  Studies should be conducted with 
the goals of: 1) demonstrating a response to 
vitamin D supplementation as a function of 
vitamin D concentration with consideration 
of other patient variables, and 2) coming to 
agreement upon a 25-hydroxyvitamin D 
serum concentration goal to be aimed for 
through vitamin D supplementation for 
specific disease states.   
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